Global Cell Therapy Human Raw Materials Market Size Likely to Grow at a CAGR of 16.3% By 2035

In 2025, the size of the global cell therapy human raw materials market is estimated to be USD 3.62 billion and it is projected to grow to USD 4.21 billion in 2026 to about USD 18.94 billion by 2035 with a CAGR of 16.3% between the periods 2026 and 2035.

Cell Therapy Human Raw Materials Market Revenue and Trends

The international cell therapy human raw materials market includes important critical products, including cell culture media, sera, cell culture supplements, reagents, cytokines, and growth factors, and other human-derived or GMP-grade cell therapies including CAR-T, stem cell therapies, and regenerative medicines. The world cell therapy human raw materials market is booming due to the increase in cell therapy clinical trials and approvals, rising prevalence of cancer and chronic diseases, rising investment in regenerative and personalised medicine, increasing biomanufacturing capacity, and increased GMP compliant, xeno-free, and serum-free formulations around the globe.

What are the Factors That Have a Significant Contribution to the Growth of the cell therapy human raw materials market?

The influx of new cell-based therapies, successful commercial roll-outs of CAR-T and other immunotherapies, and the necessity to have access to scalable cell therapy production quality raw materials with a consistent supply and, crucially, good viability, have increased its usage. The industry reports indicate that the growing rate of clinical trials and regulatory approvals of cell therapies is leading to high levels of purchase of specialized human raw materials. The developers are in need of high quality, traceable materials that have less variability and low risk of contamination as cancer, autoimmune disorders, and other indications keep increasing, necessitating higher levels of regenerative treatments.

The technological advancements have presented serum-free and chemically defined media, recombinant human proteins, closed system processing support, and elevated quality control standards, which have enhanced reproducibility, safety, and regulatory compliance. Other reasons are the increased attention on allogeneic treatments that need mass production, better supply chain stability of human-derived ingredients, and financial support of advanced therapy medicinal products (ATMPs) by the government and individual investors in both developed and emerging markets.

Segment Insight

By Product Type

Cell culture media represented the biggest portion of the cell therapy human raw materials market as of 2025, driven by the need of optimized, GMP-grade formulations that facilitate steady cell growth, activation and differentiation in therapeutic manufacturing. Such systems are also used in CAR-T, stem cell and other cell therapies, and there is intense development of xeno-free and animal component-free growth media that increase safety and scale (which is generally seen by manufacturers as a key to rapid clinical translation and commercial production).

By Distribution Channel

Direct sales by manufacturers are the largest market share and the key channel of customized, GMP-compliant materials, technical support and regulatory documentation services. These channels deliver expert qualification advice, lot-to-lot consistency assurance, and custom services to biopharma businesses, CDMOs, and research organizations with high stakes cell therapy processes, and are the channel of choice to developers with complex regulated manufacturing operations.

Regional Insights

North America has dominated the cell therapy human raw materials market because of the cell therapy well-established ecosystem, numerous approved therapies and clinical trials, intensive investments in cell therapy R&D by large biopharma companies, and biomanufacturing infrastructure. The area also enjoys good regulatory skills, availability of the best suppliers and innovative raw materials are adopted early to lead to continuous quality improvement and reliability of supplies.

In the meantime, the Asia Pacific market shows the most expedited increase in the cell therapy human raw material market, due to the booming biopharma industry, upward clinical trials, higher increase in the regenerative medicine, and the development of the manufacturing capacity. Nations such as China, India and Japan are experiencing the uptake of high quality and affordable raw materials as well as through the rise in government initiatives, local production expansiveness and collaboration on advanced therapies. The development of medical infrastructure, urbanization, and specialization in treating oncology and chronic diseases further stimulates the growth of the Asian Pacific market.

Report Scope

Recent Developments

• In October 2025: Akadeum Life Sciences and BioIVT partnered to provide superior-quality leukopaks and T cells to augment the supply of essential starting materials to develop and produce cell therapies.

List of the prominent players in the Cell Therapy Human Raw Materials Market:

• Thermo Fisher Scientific Inc.

• Merck KGaA (MilliporeSigma)

• Sartorius AG

• Albumedix Ltd.

• Takara Bio Inc.

• CellGenix GmbH

• Macopharma SA

• Miltenyi Biotec GmbH

• InVitria (Ventria Bioscience)

• PeproTech Inc. (Thermo Fisher Scientific)

• Wuhan Healthgen Biotechnology Corp.

• Others

The Cell Therapy Human Raw Materials Market is segmented as follows:

By Product Type

• Human Serum Albumin (Plasma-Derived and Recombinant)

• Human Transferrin (Plasma-Derived and Recombinant)

• Human Insulin

• Human Fibronectin and ECM Proteins

• Human Platelet Lysate (HPL)

• Recombinant Human Cytokines and Growth Factors (IL-2, IL-7, IL-15, SCF, FGF, etc.)

• Human AB Serum

• Other Human Raw Materials

By Application

• CAR-T Cell Therapy

• Stem Cell Therapy (HSC, MSC, iPSC-Derived)

• Natural Killer (NK) Cell Therapy

• Dendritic Cell Therapy

• Tumor-Infiltrating Lymphocyte (TIL) Therapy

• Other Cell Therapy Applications

By End-User

• Biopharmaceutical & Biotechnology Companies

• Academic & Research Institutes

• Contract Development and Manufacturing Organizations (CDMOs)

• Hospitals & Specialized Cell Therapy Centers

• Other End-Users

By Source

• Recombinant Human-Derived

• Plasma-Derived Human Materials

• Other Sources

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America